DaVita Inc. (NYSE:DVA) Given Consensus Rating of "Hold" by Analysts

DaVita Inc. (NYSE:DVA - Get Free Report) has received a consensus rating of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $161.80.

A number of research analysts have weighed in on DVA shares. Barclays raised their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a report on Monday, October 7th.

Institutional Trading of DaVita

A number of hedge funds have recently bought and sold shares of the business. Transcendent Capital Group LLC purchased a new stake in shares of DaVita during the 3rd quarter valued at $25,000. Blue Trust Inc. grew its position in DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company's stock valued at $54,000 after buying an additional 119 shares during the period. Quarry LP purchased a new stake in DaVita during the third quarter worth about $60,000. Point72 Hong Kong Ltd bought a new stake in DaVita in the second quarter worth about $68,000. Finally, Versant Capital Management Inc boosted its stake in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after acquiring an additional 169 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Up 0.2 %

Shares of DVA traded up $0.32 during trading hours on Wednesday, hitting $162.32. The stock had a trading volume of 478,619 shares, compared to its average volume of 590,191. DaVita has a 1-year low of $103.40 and a 1-year high of $169.51. The firm has a market capitalization of $13.31 billion, a P/E ratio of 17.51, a price-to-earnings-growth ratio of 0.86 and a beta of 0.92. The firm has a 50 day simple moving average of $156.19 and a 200-day simple moving average of $152.37. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period last year, the business posted $2.85 EPS. The company's revenue was up 4.6% on a year-over-year basis. Sell-side analysts predict that DaVita will post 9.71 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.